For over 22 years pancreatica.org has provided current, credible, and comprehensive information to those in need.
Cancer Patient’s Alliance is a 501(c)(3) non-profit organization. All donations are tax-deductible.

94% of all revenue goes towards our programs, with only 6% towards MANAGEMENT AND GENERAL EXPENSES.

Spiritual Well-being and Quality of Life for Patients Undergoing Chemotherapy

Pancreatic Cancer Blog – Commentary on Articles and Abstracts
Here is where we take complex medical articles and break them down into language you and I can understand. Click Here for more Articles and Abstracts.

Spiritual Well-being and Quality of Life for Patients Undergoing Chemotherapy
8/4/2023
    CLICK HERE for the original article or abstract

A study at the Second Affiliated Hospital of the Army Medical University in Chongqing, China, between November 2020 and April 2022, investigated the spiritual well-being and quality of life of patients receiving chemotherapy for pancreatic cancer (PC). The researchers aimed to identify factors influencing emotional and spiritual health and develop strategies to improve patients’ overall life satisfaction. 

The study included 120 PC patients undergoing chemotherapy at a hospital in China. Participants completed a questionnaire and the Functional Assessment of Chronic Illness Therapy – Spiritual Well-being Scales to assess their general contentment in life and inner peace. Findings revealed that patients reported a moderate enjoyment of life and a low-to-medium level of spiritual fulfillment. A feeling of inner balance and harmony was positively correlated with general satisfaction with life, indicating that higher spiritual health was associated with better quality of living. Patients who were middle-aged, had a low education level, low family income, disease recurrence, and moderate-to-severe pain had less peace of mind and less contentment in life. 

The study suggests that healthcare providers should provide additional care and support to protect the sense of serenity of these patients, ultimately improving their satisfaction with life. By addressing these factors and implementing spiritual-care plans, clinicians can potentially enhance the general well-being and happiness of PC patients undergoing chemotherapy.

Stay Informed, Stay Empowered: Your Trusted Source for Pancreatic Cancer News, Knowledge, Stories, and More.

Subscribe

* indicates required

For over 22 years pancreatica.org has provided current, credible, and comprehensive information to those in need. Cancer Patient’s Alliance is a 501(c)(3) non-profit organization. All donations are tax-deductible.

We Put All Donations To Serious Use Toward The Mission Of Fighting Pancreatic Cancer. 

We believe in strong patient-physician bonds, scientifically-based treatment, and that comfort can come from knowing that everything that reasonably can be done – is being done.

94% OF ALL REVENUE GOES TOWARDS OUR PROGRAMS, WITH ONLY 6% TOWARDS MANAGEMENT AND GENERAL EXPENSES.

Cancer Patient’s Alliance is proud to have earned a Platinum rating on Guidestar.
Click Here for Candid’s Guidestar

Gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: a Comparison

Pancreatic Cancer Blog – Commentary on Articles and Abstracts
Here is where we take complex medical articles and break them down into language you and I can understand. Click Here for more Articles and Abstracts.

Comparing Two Chemotherapy Treatments for Advanced Pancreatic Cancer: Gem-Nab and Gem-Ox

8/8/2023

    CLICK HERE for the original article or abstract

One of the common chemotherapy treatments used worldwide is a combination of Gemcitabine and nab-paclitaxel, also known as Gem-Nab. However, this medication isn’t always available or covered by insurance.

The researchers in this study wanted to see how effective Gem-Nab was compared to another therapy regimen called gemcitabine and oxaliplatin, known as Gem-Ox. Gem-Ox was the standard treatment at their cancer center in Saltzburg, Austria before a newer medication called FOLFIRINOX was introduced. To compare the two therapies, the researchers looked at the medical records of 121 patients with advanced pancreatic adenocarcinoma who received either Gem-Nab or Gem-Ox as their first-line chemotherapy.

They found that out of the 554 patients they screened, 73 were treated with Gem-Nab and 48 with Gem-Ox. Those who received Gem-Ox had a better performance score, which means they were healthier overall, compared to the Gem-Nab group. They were also more likely to have locally advanced disease instead of metastatic disease, and they were younger.

When it came to survival rates, there wasn’t a significant difference between the two groups. The median overall survival for the entire study group was around 10.3 months, with no significant difference between the Gem-Nab and Gem-Ox groups. The same went for progression-free survival, which was around 6.8 months for the whole group.

They also looked at other factors like gender, age, performance status, and CA19-9 levels, but adjusting for these factors didn’t change the results. In other words, there wasn’t a statistically significant difference in the outcomes between Gem-Nab and Gem-Ox.

Based on these findings, the researchers suggest that Gem-Ox could be a potential first-line treatment option for patients with inoperable locally advanced or metastatic pancreatic cancer, especially if Gem-Nab is not available.

So, in a nutshell, this study compared two different chemotherapy treatments for pancreatic cancer and found that there wasn’t a significant difference in the outcomes between the two. This suggests that Gem-Ox could be a viable option for patients who can’t receive Gem-Nab.

Stay Informed, Stay Empowered: Your Trusted Source for Pancreatic Cancer News, Knowledge, Stories, and More.

Subscribe

* indicates required

For over 22 years pancreatica.org has provided current, credible, and comprehensive information to those in need. Cancer Patient’s Alliance is a 501(c)(3) non-profit organization. All donations are tax-deductible.

We Put All Donations To Serious Use Toward The Mission Of Fighting Pancreatic Cancer. 

We believe in strong patient-physician bonds, scientifically-based treatment, and that comfort can come from knowing that everything that reasonably can be done – is being done.

94% OF ALL REVENUE GOES TOWARDS OUR PROGRAMS, WITH ONLY 6% TOWARDS MANAGEMENT AND GENERAL EXPENSES.

Cancer Patient’s Alliance is proud to have earned a Platinum rating on Guidestar.
Click Here for Candid’s Guidestar

Using Two Drugs Together in Chemotherapy an Improved Method

Pancreatic Cancer Blog – Commentary on Articles and Abstracts
Here is where we take complex medical articles and break them down into language you and I can understand. Click Here for more Articles and Abstracts.

Using Two Drugs Together in Chemotherapy: an Improved Method

7/31/2023

CLICK HERE for the original article or abstract !

A new treatment was approved in Japan in 2020 called nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/levo-leucovorin (Levo-LV). One drawback was that this regimen required a long administration time because the Levo-LV had to be given separately after the nal-IRI.

Since this was causing a burden on both patients and the outpatient chemotherapy room, the hospital decided to try a new approach called parallel administration. This means that they started giving the nal-IRI and Levo-LV at the same time. The hospital reviewed the data of 69 patients who received this treatment between June 2020 and October 2021 to see if the parallel method was safe and effective.

They found that there were no problems with giving the drugs simultaneously, and there were no major differences in how well the treatment worked or in the side effects compared to the conventional method. However, the parallel method did have a significant advantage in that it reduced the administration time, making it more convenient for patients and healthcare workers.

So, the conclusion of the study is that the parallel administration of nal-IRI and Levo-LV is a safe and effective method for treating pancreatic cancer. It also saves time, which is a big advantage for everyone involved.

Stay Informed, Stay Empowered: Your Trusted Source for Pancreatic Cancer News, Knowledge, Stories, and More.

Subscribe

* indicates required

For over 22 years pancreatica.org has provided current, credible, and comprehensive information to those in need. Cancer Patient’s Alliance is a 501(c)(3) non-profit organization. All donations are tax-deductible.

We Put All Donations To Serious Use Toward The Mission Of Fighting Pancreatic Cancer. 

We believe in strong patient-physician bonds, scientifically-based treatment, and that comfort can come from knowing that everything that reasonably can be done – is being done.

94% OF ALL REVENUE GOES TOWARDS OUR PROGRAMS, WITH ONLY 6% TOWARDS MANAGEMENT AND GENERAL EXPENSES.

Cancer Patient’s Alliance is proud to have earned a Platinum rating on Guidestar.
Click Here for Candid’s Guidestar

Aspirin May Boost Gemcitabine Effectiveness

Pancreatic Cancer Blog – Commentary on Articles and Abstracts
Here is where we take complex medical articles and break them down into language you and I can understand. Click Here for more Articles and Abstracts.

Aspirin May Boost Gemcitabine Effectiveness
8/8/2023
CLICK HERE for the original article or abstract

At the First Affiliated Hospital of Nanjing Medical University, in Nanjing, China, a recent study has found that using aspirin in combination with gemcitabine, a standard medication for pancreatic cancer, can significantly enhance its effectiveness. The study aimed to explore the impact of aspirin on gemcitabine’s efficacy in pancreatic cancer and its underlying mechanism. The researchers treated human pancreatic cell lines with aspirin and gemcitabine and examined their effects.

The results showed that aspirin increased gemcitabine’s ability to reduce the growth, migration, and invasion of pancreatic cancer cells while promoting apoptosis (cell death). These positive effects were found to be connected to blocking a specific signaling pathway (PI3K/AKT/mTOR) and reversing a cellular transformation process (epithelial-mesenchymal transition or EMT) that are both related to the advancement and spread of cancer.

Based on these findings, the study suggests that combining aspirin with gemcitabine could be a promising therapeutic approach for patients. This combination treatment may enhance the overall effectiveness of gemcitabine while potentially reducing the risk of cancer spread and progression.

AI for reading pancreatic cancer radiographs

Pancreatic Cancer Blog – Commentary on Articles and Abstracts
Here is where we take complex medical articles and break them down into language you and I can understand. Click Here for more Articles and Abstracts.

AI for reading pancreatic cancer radiographs

8/22/2023

CLICK HERE for the original article or abstract !

The study under discussion provides an in-depth review of advancements in artificial intelligence (AI) technologies, particularly deep learning and radiomics, as they relate to the early and accurate diagnosis of pancreatic cancer. The focus is on using these technologies to analyze cross-sectional imaging examinations like computed tomography (CT) scans and magnetic resonance imaging (MRI). Let’s break down the key points:

Purpose of the Study

The primary aim is to examine how emerging AI algorithms could significantly improve the diagnosis of pancreatic cancer, an often aggressive disease where early detection is crucial for favorable outcomes.

Recent Advances

  1. Deep Learning: This subset of AI revolves around advanced algorithms that allow the system to learn from data autonomously. In medical imaging:
    • Convolutional Neural Networks (CNNs): These are particularly effective at image analysis. They scrutinize medical scans meticulously, identifying subtle features that may be indicative of cancer.
    • Transformer-based Models: These are even more advanced and capable of multi-faceted analysis. They can look at multiple types of lesions and integrate other types of information, which is a significant step forward.
  2. Radiomics: This involves extracting a high amount of features from radiological images, leading to a wealth of data that can be further analyzed. This methodology has been refined with improved feature extraction techniques and machine learning classifiers, which help in sorting and interpreting this data more accurately.

Practical Implications

  1. Improved Diagnostic Accuracy: The ability of AI to analyze minute details in medical images offers the promise of much greater diagnostic accuracy, which is crucial for a disease as serious as pancreatic cancer.

  2. Personalized Treatment Plans: With better diagnosis comes the ability to tailor treatment plans to individual patients, thereby improving the likelihood of successful outcomes.

  3. Predictive Biomarkers: These technologies have the potential to identify biomarkers that can help predict treatment responses, further aiding personalized medicine.

Challenges and Limitations

Despite these promising developments, the study notes that there is still work to be done in translating these advancements into clinical practice. The focus of ongoing research needs to be on refining these methods, ensuring their reliability, and integrating them seamlessly into existing healthcare workflows.

In summary, the intersection of AI technologies and medical imaging is showing significant promise for the early and accurate diagnosis of pancreatic cancer. While challenges remain, the advancements are laying a solid foundation for future research and practical applications.

Stay Informed, Stay Empowered: Your Trusted Source for Pancreatic Cancer News, Knowledge, Stories, and More.

Subscribe

* indicates required

For over 22 years pancreatica.org has provided current, credible, and comprehensive information to those in need. Cancer Patient’s Alliance is a 501(c)(3) non-profit organization. All donations are tax-deductible.

We Put All Donations To Serious Use Toward The Mission Of Fighting Pancreatic Cancer. 

We believe in strong patient-physician bonds, scientifically-based treatment, and that comfort can come from knowing that everything that reasonably can be done – is being done.

94% OF ALL REVENUE GOES TOWARDS OUR PROGRAMS, WITH ONLY 6% TOWARDS MANAGEMENT AND GENERAL EXPENSES.

Cancer Patient’s Alliance is proud to have earned a Platinum rating on Guidestar.
Click Here for Candid’s Guidestar

WordPress › Error

There has been a critical error on this website.

Learn more about troubleshooting WordPress.